Please login to the form below

Not currently logged in
Email:
Password:

Sylvant

This page shows the latest Sylvant news and features for those working in and with pharma, biotech and healthcare.

EC approves Janssen rare blood disorder drug

EC approves Janssen rare blood disorder drug

Sylvant (siltuximab) offers a more promising alternative, however, and has demonstrated in clinical trials it can reduce the size of tumours and stabilise disease symptoms, such as fever. ... The European Commission's decision to greenlight Sylvant comes

Latest news

  • FDA approves Janssen drug for rare Castleman’s disease FDA approves Janssen drug for rare Castleman’s disease

    Due to the severity of the disease and lack of current treatment options Sylvant was assessed by the FDA under its priority review programme. ... Sylvant is also under review in the EU where Janssen submitted a drug filing in September last year. .

  • EMA backs Janssen rare disease drug for approval EMA backs Janssen rare disease drug for approval

    Castleman's disease treatment Sylvant wins CHMP recommendation. J&J subsidiary Janssen-Cilag's Castleman's disease treatment Sylvant (situximab) has been recommended for approval in Europe. ... Sylvant, which was filed for approval in Europe and the US

  • Boehringer/Lilly's empagliflozin among CHMP recommendations Boehringer/Lilly's empagliflozin among CHMP recommendations

    There were also recommendations for four orphan drugs: Janssen-Cilag's Sylvant (situximab) and, along with the companion diagnostic drugs Folcepri (etarfolatide) and Neocepri (folic acid), Endocyte's Vynfinit (vintafolide).

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics